Liquidia Technologies
  |   |   |
   Home  |  Site Map  |  Contact Us  
  

Liquidia utilizes a proprietary PRINT Technology platform.
Product Platform

Introduction
Vaccines
Inhaled Therapeutics
Ophthalmology
Other Programs
Publications
Ophthalmology:
 


To address critical unmet needs in ophthalmology, Liquidia has formed a new company that is leveraging the proprietary PRINT technology platform to rationally design and manufacture micro- and nano-particle systems for the treatment of ocular diseases.  The company, Envisia Therapeutics, has the ability to engineer therapeutic particles with tunable release kinetics that could significantly reduce dosing requirements and increase patient compliance, which is currently a significant challenge in the treatment of ocular disease.

For more information about Envisia Therapeutics, visit the company website.


© 2013 Liquidia Technologies | PO Box 110085 | Research Triangle Park, NC 27709 | P.919.328.4400 | F.919.328.4402 | email: info@liquidia.com